Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 6liposomal doxorubicin 4Carboplatin 4Topotecan 3Drug Therapy 3Gemcitabine 2Doxorubicin 2Bevacizumab 21-dodecylpyridoxal 2trametinib 1saracatinib 1pertuzumab 1pembrolizumab 1pegfilgrastim 1olaparib 1masitinib 1dabrafenib 1cyclopropapyrroloindole 1cobimetinib 1cediranib 1atezolizumab 1aflibercept 1abagovomab 1Vemurafenib 1Trastuzumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1NP-G2-044 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Ovarian Neoplasms × cyclopropapyrroloindole × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡